Ovarian cancer

Showing 2 of 0 results

• The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

  Poster presented at: ASCO 2024; May 31-June 4, 2024; Chicago, IL

  • Publication summary
  • Publications
  • Ovarian cancer
• Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Drug discovery
  • Ovarian cancer